Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alzheon reports Phase I bridging dose analysis data for AD candidate ALZ-801

Based on a bridging dose analysis of 3 placebo-controlled Phase I trials evaluating the safety and pharmacokinetics of various dosing regimens and formulations of Alzheimer’s disease candidate ALZ-801 in 127 healthy

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE